BioSpace News Archive

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154, the world’s first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, compared to a conventional mRNA COVID-19 vaccine.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release 2023 fourth quarter and full year financial and operational results on Thursday, February 15, 2024, before markets open.

Tharimmune, Inc. announced today the first patient dosed in the Company’s Phase 1 clinical trial with TH104, utilizing a proprietary oral thin film.

Aspero Medical had previously received clearance from the Food and Drug Administration (FDA) to market and sell the Ancora-SB small bowel balloon overtube which incorporates the company’s patented Pillar micro-texture balloon technology.

ProLynx Inc. announced today that the first patient was treated with PLX038 (PEGylated SN-38) in a Phase I/II clinical trial for primary CNS tumors driven by MYC or MYCN amplifications.

Intelligent Bio Solutions Inc. today announced an agreement between the Company and several current warrant holders to exercise certain existing Series E Warrants (the “Existing Warrants”) to purchase up to an aggregate of 606,064 shares of common stock.

Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed a memorandum of understanding with AstraZeneca China to establish a research and development collaboration at AstraZeneca’s Innovation Campus in Chengdu, China.

In a major scientific breakthrough, a research team from King Faisal Specialist Hospital and Research Centre, in collaboration with King Abdullah University of Science and Technology, working alongside researchers from the UK, the US, and India, discovered a vital gene instrumental in combating malaria.

TerSera Therapeutics LLC announced today that The National Comprehensive Cancer Network® (NCCN) Breast Cancer Panel included both goserelin 3.6 mg every 4 weeks and goserelin 10.8 mg every 12 weeks, as methods for ovarian function suppression in Version 1.2024 of the Breast Guidelines revised as of January 25, 2024.

DirectMed Imaging announces Technical Prospects, the company it acquired in August of 2023, will now fully join forces under the DirectMed Imaging name.